Gil Verschelden

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib

Amir Noeparast, Erik Teugels, Philippe Giron et al. · Oncotarget · 2016 · 100 citations · Full text

Medicine, Oncology, Pharmacology +16

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Marius Trøseid, José Ramón Arribas, Lambert Assoumou et al. · Critical Care · 2023 · 47 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10

Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: An observational study

Gil Verschelden, Maryam Noparast, Maïlis Lauwers et al. · International Immunopharmacology · 2021 · 16 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +7

Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial

Vida Terzić, Joe Miantezila Basilua, Nicolas Billard et al. · Clinical Infectious Diseases · 2024 · 13 citations · Full text

Health Professions, Internal Medicine, Pharmacotherapy +15

Erdheim-Chester disease: a case report and literature review

Gil Verschelden · VUBIR (Vrije Universiteit Brussel) · 2017 · 12 citations

Medicine, Pathology, Genodermatoses +2